These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6117153)

  • 1. Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
    Wray SR; Melville GN; Grell GA; Edge PC
    West Indian Med J; 1981 Sep; 30(3):107-18. PubMed ID: 6117153
    [No Abstract]   [Full Text] [Related]  

  • 2. GABA and movement disorders.
    Marsden CD; Sheehy MP
    Adv Biochem Psychopharmacol; 1981; 30():225-34. PubMed ID: 6460427
    [No Abstract]   [Full Text] [Related]  

  • 3. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
    Stahl SM; Davis KL; Berger PA
    J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotransmitter interactions related to central dopamine neurons.
    Lloyd KG
    Essays Neurochem Neuropharmacol; 1978; 3():129-207. PubMed ID: 30628
    [No Abstract]   [Full Text] [Related]  

  • 5. GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions.
    Scheel-Krüger J
    Adv Neurol; 1984; 40():85-90. PubMed ID: 6141713
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory peptides in animal paradigms of neuropsychiatric illness.
    Diamond BI; Borison RL
    Adv Biochem Psychopharmacol; 1982; 33():541-8. PubMed ID: 6214928
    [No Abstract]   [Full Text] [Related]  

  • 7. Dysphagia in movement disorders.
    Logemann JA
    Adv Neurol; 1988; 49():307-16. PubMed ID: 2964174
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study.
    Grabli D; McCairn K; Hirsch EC; Agid Y; Féger J; François C; Tremblay L
    Brain; 2004 Sep; 127(Pt 9):2039-54. PubMed ID: 15292053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Movement disorders: why don't those synapses fire?
    Zemlak V; Woldehana A
    Axone; 1992 Dec; 14(2):46-9. PubMed ID: 1337267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain neurotransmitters and neuromodulators in pediatrics.
    Johnston MV; Singer HS
    Pediatrics; 1982 Jul; 70(1):57-68. PubMed ID: 6123978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tardive dyskinesia: clinical picture, prevalence, and pathophysiology].
    Wöller W; Tegeler J
    Fortschr Neurol Psychiatr; 1983 Apr; 51(4):131-57. PubMed ID: 6134658
    [No Abstract]   [Full Text] [Related]  

  • 14. Growth hormone secretion in neurological disorders.
    Martinez-Campos A; Giovannini P; Cocchi D; Zanardi P; Parati EA; Caraceni T; Müller EE
    Adv Biochem Psychopharmacol; 1981; 28():521-40. PubMed ID: 6452036
    [No Abstract]   [Full Text] [Related]  

  • 15. Tardive dyskinesia: a biological appraoch.
    Barbaccia ML; Trabucchi M
    Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
    [No Abstract]   [Full Text] [Related]  

  • 16. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in neural networks by conditional transgenic approach: a key to our comprehension of neuro-psychiatric disorders in the basal ganglia system].
    Schiffmann SN
    Bull Mem Acad R Med Belg; 2009; 164(7-9):171-8; discussion 178-80. PubMed ID: 20218186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Movement disorders in the elderly.
    Gilmore R
    Geriatrics; 1984 Jun; 39(6):65-8, 72-6. PubMed ID: 6144615
    [No Abstract]   [Full Text] [Related]  

  • 19. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation.
    Davis KL; Hollister LE; Berger PA; Barchas JD
    Psychopharmacol Commun; 1975; 1(5):533-43. PubMed ID: 132684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catecholamines and neurologic diseases (second of two parts).
    Moskowitz MA; Wurtman RJ
    N Engl J Med; 1975 Aug; 293(7):332-8. PubMed ID: 125386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.